We found that the most frequent genomic aberrations in these NSCLC patients were TP53 (47%), KIT (31%), KRAS (28%), EGFR (21%), PIK3CA (14%), c-MET (11%), BRAF (9%), STK11 (9%), ATM (8%), CDKN2A (7%), and APC (5%) mutations, which were similar to previously reported genomic aberrations [29, 30]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.